A Case of der(19)t(1;19) in Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis.
- Author:
Yirang LEE
1
;
Ji Young PARK
;
Young Kyung LEE
;
Hyun Soo KIM
;
Kyu Sung SHIN
;
Joo Young JUNG
;
Hyoun Chan CHO
Author Information
- Publication Type:Case Report
- Keywords: t(1; 19)(q23; p13); Refractory anemia; Ring sideroblasts; Thrombocytosis; TCF3-PBX1
- MeSH: Anemia; Anemia, Refractory; Blood Transfusion; Bone Marrow; Humans; Hydroxyurea; Hyperplasia; Iron; Karyotyping; Polymerase Chain Reaction; Thrombocytosis
- From:Laboratory Medicine Online 2013;3(2):110-114
- CountryRepublic of Korea
- Language:Korean
- Abstract: Translocation between chromosomes 1 and 19 is well documented in ALL. Here, we report a case of refractory anemia with ring sideroblasts associated with marked thrombocytosis with der(19)t(1;19). A 67-yr-old man was admitted to our hospital with anemia and thrombocytosis. The aspirated bone marrow showed erythroid and megakaryocytic hyperplasia and dyspoiesis. Iron staining showed that the ring sideroblasts increased in number. Bone-marrow cell karyotyping showed 46,XY,der(19)t(1;19)(q23;p13)[9]/46,XY,del(5)(q21)[2]/46,XY[9]. PCR analysis showed the absence of the TCF3-PBX1 rearrangement. The patient was treated with hydroxyurea and intermittent blood transfusion. It is known that t(1;19)(q23;p13) leads to a TCF3-PBX1 fusion gene, whose product is a powerful transcriptional activator that plays a key role in the development of ALL. However, t(1;19) has rarely been reported in myeloid neoplasms and the TCF3-PBX1 fusion gene has not been detected. This implies that other genes might be involved in the TCF3-PBX1 rearrangement, or an alternative TCF3-PBX1 fusion transcript with a different breakpoint has not been detected to date. Further research and case studies, including the use of molecular analysis techniques, are required to evaluate the clinical and prognostic significance of t(1;19) in the development of myeloid neoplasms.
